Editorial - Don't buyback in anger

CME Group’s attempt to close out its protracted Nymex deal by way of a share buy-back scheme could look like a last ditch attempt at salvaging a purchase that had appeared as if it was starting to slip away. The fact that CME has had to resort to upping the stakes in return for securing the New York commodities exchange shows that it...